MS
REGN icon

Millington Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Millington Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Buy
+261
New +$200K 0.06% 274

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millington Securities's REGN Position: Q1 2026 in Review

Millington Securities opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 261 shares worth $202K. The stake represents 0.06% of the portfolio and ranks #274 among its holdings.

1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Millington Securities held 261 shares of Regeneron Pharmaceuticals worth $202K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Millington Securities position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.06% of Millington Securities's portfolio in Q1 2026, its #274 holding.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Millington Securities's 13F filing for Q1 2026, filed 15 Jul 2026.